## Eric M Yoshida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8574819/publications.pdf

Version: 2024-02-01

113 papers

2,098 citations

331259 21 h-index 243296 44 g-index

114 all docs

114 docs citations

times ranked

114

3042 citing authors

#	Article	lF	CITATIONS
1	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 685-697.	4.6	402
2	Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transplantation, 2001, 7, 811-815.	1.3	252
3	Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial. Liver Transplantation, 2005. 11. 1064-1072.	1.3	138
4	Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplantation, 1999, 5, 520-525.	1.9	128
5	Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Journal of Hepatology, 2017, 66, 504-513.	1.8	82
6	Drug Interactions With Direct-Acting Antivirals for Hepatitis C. Annals of Pharmacotherapy, 2015, 49, 674-687.	0.9	73
7	Obstacles to Residents $\hat{E}$ Conducting Research and Predictors of Publication. Academic Medicine, 2001, 76, 477.	0.8	65
8	Liver injury after SARSâ€CoVâ€2 vaccination: Features of immuneâ€mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology, 2022, 76, 1576-1586.	3.6	58
9	Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. Journal of Hepatology, 2014, 60, 748-756.	1.8	37
10	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 936-942.	1.4	37
11	Obstetrical and Neonatal Outcomes Among Women Infected With Hepatitis C and Their Infants. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 785-794.	0.3	35
12	Validation of Risk Scoring Systems in Ursodeoxycholic Acid–Treated Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2019, 114, 1101-1108.	0.2	34
13	The impact of SVR from directâ€acting antiviral―and interferonâ€based treatments for HCV on hepatocellular carcinoma risk. Journal of Viral Hepatitis, 2020, 27, 781-793.	1.0	34
14	What Has the COVID-19 Pandemic Taught Us so Far? Addressing the Problem from a Hepatologist's Perspective. Journal of Clinical and Translational Hepatology, 2020, 8, 109-112.	0.7	33
15	Common variation near IRF6 is associated with IFN- $\hat{l}^2$ -induced liver injury in multiple sclerosis. Nature Genetics, 2018, 50, 1081-1085.	9.4	32
16	Biomarkers for hepatocellular cancer. World Journal of Hepatology, 2020, 12, 558-573.	0.8	30
17	Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. Annals of Hepatology, 2016, 15, 154-9.	0.6	29
18	Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis. Digestive Diseases and Sciences, 2018, 63, 1348-1354.	1.1	27

#	Article	IF	CITATIONS
19	Obscure Gastrointestinal Bleeding from an Ampullary Tumour in a Patient with a Remote History of Renal Cell Carcinoma: A Diagnostic Conundrum. Canadian Journal of Gastroenterology & Hepatology, 1998, 12, 75-78.	1.8	26
20	Effects of immunosuppressive drugs on COVIDâ€19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	1.9	26
21	Postliver Transplant Allograft Reinfection with a Lamivudine-Resistant Strain of Hepatitis B Virus: Long Term Follow-up. Canadian Journal of Gastroenterology & Hepatology, 1998, 12, 125-129.	1.8	24
22	Clinical and Endoscopic Significance of Bowel-Wall Thickening Reported on Abdominal Computed Tomographies in Symptomatic Patients with No History of Gastrointestinal Disease. Canadian Association of Radiologists Journal, 2014, 65, 67-70.	1.1	24
23	Loss to followâ€up: A significant barrier in the treatment cascade with directâ€acting therapies. Journal of Viral Hepatitis, 2020, 27, 243-260.	1.0	22
24	Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS ONE, 2015, 10, e0138907.	1.1	22
25	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting. PLoS ONE, 2017, 12, e0185198.	1.1	22
26	Effect of socioeconomic status on hepatocellular carcinoma incidence and stage at diagnosis, a populationâ€based cohort study. Liver International, 2016, 36, 902-910.	1.9	21
27	Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study. Open Forum Infectious Diseases, 2020, 7, ofaa055.	0.4	20
28	Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Annals of Hepatology, 2017, 16, 188-197.	0.6	19
29	Late Recurrent Post-Transplant Primary Biliary Cirrhosis in British Columbia. Canadian Journal of Gastroenterology & Hepatology, 1997, 11, 229-233.	1.8	18
30	Costâ€effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with personâ€evel data in a Canadian setting. Cancer Medicine, 2017, 6, 2017-2033.	1.3	18
31	Risk of Stroke in Liver Cirrhosis. Journal of Clinical Gastroenterology, 2020, 54, 96-105.	1.1	17
32	Inflammatory Pseudotumor of the Liver: A Rare Case of Recurrence Following Surgical Resection. Journal of Radiology Case Reports, 2014, 8, 23-30.	0.2	16
33	Primary Biliary Cholangitis in British Columbia First Nations: Clinical features and discovery of novel genetic susceptibility loci. Liver International, 2018, 38, 940-948.	1.9	16
34	Let's Talk About B: Barriers to Hepatitis B Screening and Vaccination Among Asian and South Asian Immigrants in British Columbia. Journal of Racial and Ethnic Health Disparities, 2018, 5, 1337-1345.	1.8	16
35	Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease. World Journal of Gastroenterology, 2014, 20, 12657.	1.4	16
36	Indications for Liver Tranplantation in British Columbia's Aboriginal Population: A 10-Year Retrospective Analysis. Canadian Journal of Gastroenterology & Hepatology, 2000, 14, 775-779.	1.8	14

#	Article	IF	Citations
37	Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Current Infectious Disease Reports, 2016, 18, 22.	1.3	14
38	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Multiple Sclerosis and Related Disorders, 2013, 2, 57-59.	0.9	12
39	A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-10.	0.8	12
40	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. CMAJ Open, 2018, 6, E664-E670.	1.1	12
41	Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 180-184.	1.8	11
42	Public awareness of acetaminophen and risks of drug induced liver injury: Results of a large outpatient clinic survey. PLoS ONE, 2020, 15, e0229070.	1.1	10
43	Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis. Annals of Hepatology, 2021, 20, 100211.	0.6	9
44	Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Annals of Hepatology, 2014, 13, 525-32.	0.6	9
45	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. Clinical and Translational Gastroenterology, 2021, 12, e00409.	1.3	8
46	Remission of Multiple Sclerosis Post-Liver Transplantation. Canadian Journal of Neurological Sciences, 2004, 31, 539-541.	0.3	7
47	Transplantation as disease modifying therapy in adults with inherited metabolic disorders. Journal of Inherited Metabolic Disease, 2018, 41, 885-896.	1.7	7
48	A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Annals of Hepatology, 2014, 13, 364-75.	0.6	7
49	Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Annals of Hepatology, 2013, 12, 282-93.	0.6	6
50	Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience. Annals of Hepatology, 2018, 17, 437-443.	0.6	5
51	In-hospital post-transplant acute hepatitis A viral (HAV) infection in a liver transplant recipient who was HAV seropositive pre-transplant. Saudi Journal of Gastroenterology, 2019, 25, 67.	0.5	5
52	Elevated serum ferritin in non-alcoholic fatty liver disease is not predictive of fibrosis. Canadian Liver Journal, 2022, 5, 152-159.	0.3	5
53	Seroprevalences of Hepatitis B Virus and Hepatitis C Virus among Participants of an Asian Health Fair in the Lower Mainland, British Columbia. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 196-200.	0.7	4
54	COVID-19 in gastroenterology and hepatology: Living with the realities of a historic 21stcentury pandemic. Saudi Journal of Gastroenterology, 2020, 26, 223.	0.5	4

#	Article	IF	CITATIONS
55	Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008–2019. PLoS ONE, 2020, 15, e0244575.	1.1	4
56	The effect of doxorubicin loading on response and toxicity with drug-eluting embolization in resectable hepatoma: a dose escalation study. Anticancer Research, 2014, 34, 3597-606.	0.5	4
57	Acute Pseudohepatitis in a Chronic Substance Abuser Secondary to Occult Seat Belt Injury. Canadian Journal of Gastroenterology & Hepatology, 1999, 13, 155-158.	1.8	3
58	Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-4.	0.7	3
59	Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Biomedicine and Pharmacotherapy, 2021, 143, 112195.	2.5	3
60	End stage liver disease etiology & transplantation referral outcomes of major ethnic groups in British Columbia, Canada. Medicine (United States), 2021, 100, e27436.	0.4	3
61	Patientâ€specific genetic factors predict treatment failure in sofosbuvirâ€ŧreated patients with chronic hepatitis C. Liver International, 2022, 42, 796-808.	1.9	3
62	Diabetes Mellitus After Liver Transplantation: Another Extrahepatic Manifestation of Hepatitis C. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 432-432.	1.8	2
63	Exploring the psychological effects of deceased organ donation on the families of the organ donors $\hat{a} \in \mathbb{C}$ a response. Clinical Transplantation, 2008, 22, 687-687.	0.8	2
64	Alpha Fetoprotein-Secreting Gastric Cancer in the Setting of Chronic Hepatitis B: The Role of Endoscopy. ACG Case Reports Journal, 2015, 2, 152-154.	0.2	2
65	Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission. Transplantation Direct, 2018, 4, e347.	0.8	2
66	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. Annals of Hepatology, 2019, 18, 651-654.	0.6	2
67	Assessing Maternity Care Providers' Knowledge of the Management of Hepatitis B in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2019, 41, 616-622.	0.3	2
68	Review of pharmacotherapeutic treatments for primary sclerosingÂcholangitis. Canadian Liver Journal, 2019, 2, 58-70.	0.3	2
69	Isolated Liver Rejection After Lung and Combined Kidney-Liver Transplantation: A Case Report. Transplantation Proceedings, 2021, 53, 1333-1336.	0.3	2
70	Comparing the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score with transient elastography scores of people with non-alcoholic fatty liver disease. Canadian Liver Journal, 2021, 4, 275-282.	0.3	2
71	Hepatic artery interruption followed by portal vein thrombosis in an adult liver transplant. Transplant International, 1994, 7, 434-437.	0.8	2
72	A national paucity of hepatologists: An unprecedented opportunity for interdisciplinary collaboration. Canadian Liver Journal, 2021, 4, 343-345.	0.3	2

#	Article	IF	CITATIONS
73	Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate. World Journal of Hepatology, 2015, 7, 2559.	0.8	2
74	Non-alcoholic fatty liver disease (NAFLD) in Filipino North American patients: Results from a multi-ethnic cohort. Canadian Liver Journal, 2022, 5, 4-13.	0.3	2
75	N-acetylcysteine for non-acetaminophen induced acute liver failure: A review. Saudi Journal of Gastroenterology, 2022, 28, 85.	0.5	2
76	Ukraine strong. Canadian Liver Journal, 0, , .	0.3	2
77	Hepatic artery interruption followed by portal vein thrombosis in an adult liver transplant. Transplant International, 1994, 7, 434-437.	0.8	1
78	Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy. European Journal of Gastroenterology and Hepatology, 2004, 16, 355-358.	0.8	1
79	Canadian Resident Research Projects and Peer-Reviewed Publication. Canadian Journal of Hospital Pharmacy, 2013, 66, 257.	0.1	1
80	Disseminated herpes simplex virus 2 (HSV-2) encephalitis in a liver transplant recipient: Potential implications for liver transplant programs. Jammi, 2018, 3, 146-148.	0.3	1
81	Application of Risk Scores in the Daily Management of Primary Biliary Cholangitis: Response to Corpechot and Chazouillà res. American Journal of Gastroenterology, 2019, 114, 1692-1692.	0.2	1
82	Stability of hepatitis B viral load during pregnancy and implications for antepartum prophylaxis: A prospective cohort study. Canadian Liver Journal, 2019, 2, 190-198.	0.3	1
83	Hepatology in the time of COVID-19. Canadian Liver Journal, 2020, 3, 163-164.	0.3	1
84	Terlipressin and albumin: The good, the bad, and the unattractive (with apologies to Sergio Leone). Canadian Liver Journal, 2021, 4, 340-342.	0.3	1
85	Retrospective Review of Patients of Southeast Asian Descent with Persistent Hyperferritinemia Who Are Negative for Hereditary Hemochromatosis Blood, 2006, 108, 3737-3737.	0.6	1
86	Post-partum Primary Biliary Cholangitis Preceded by Intrahepatic Cholestasis of Pregnancy in Three First Nation Patients. Digestive Diseases and Sciences, 2021, 66, 1367-1369.	1.1	1
87	Black Lives Matter: Hepatologists and the duty to oppose systemicÂand non-systemic racism and bias. Canadian Liver Journal, 2020, 3, 235-236.	0.3	1
88	Occult Hepatitis B Reactivation after Liver Transplant: The Role of a Novel Mutation in the Surface Antigen. Journal of Clinical and Translational Hepatology, 2020, 000, 1-3.	0.7	1
89	Rosuvastatin and chronic hepatitis C. Hepatitis Monthly, 2011, 11, 384-5.	0.1	1
90	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 375-381.	0.6	1

#	Article	IF	Citations
91	Checkpoint inhibition in hepatocellular carcinoma: Outsmarting the <i>Squid Game</i> . Canadian Liver Journal, 2022, 5, 165-168.	0.3	1
92	An Unusual Presentation of Metastatic Squamous Cell Cervical Carcinoma Involving the Distal Ileum Mimicking Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 1994, 8, 323-325.	1.8	0
93	Liver Enzymes as Surrogate Markers of Hepatitis C Histopathology – Avoiding the Liver Biopsy Needle?. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 629-630.	1.8	0
94	Efficacy of Lamivudine in Decompensated Cirrhosis Secondary to Hepatitis B: Cautious Optimism in the War Not Yet Won. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 433-434.	1.8	0
95	Postliver Transplant Immunosuppression: The Song DoesNotRemain the Same. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 65-66.	1.8	0
96	The journey Continues. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 175-175.	0.8	0
97	Academic Outcomes and Utility of Gastroenterology Residents In-Training Course Abstract Presentations: The University of British Columbia Experience. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-2.	0.8	0
98	Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature. Journal of Clinical Virology, 2016, 79, 51-53.	1.6	0
99	Transplanting Kidney Allografts from Hepatitis C Infected Donors into Hepatitis C Uninfected Recipients: Re-Thinking the Thinker Trial. Annals of Hepatology, 2017, 16, 702-703.	0.6	0
100	Annals of Hepatology: Viewpoints from Afar. Annals of Hepatology, 2018, 17, 4-7.	0.6	0
101	Transplanting Hepatitis C–Seropositive, Nucleic Acid Test–Negative Donor Organs Into Hepatitis C–Negative Recipients. Hepatology, 2018, 68, 1208-1209.	3.6	0
102	Alcohol product warning labels to deter alcohol misuse and prevent alcohol-related diseases: a call to action in Canada. Canadian Liver Journal, 2021, 4, 75-78.	0.3	0
103	The Canadian Liver Journal: The voice of CASL and Canadian hepatology. Canadian Liver Journal, 2018, 1, 1-2.	0.3	0
104	Early liver transplant for severe alcoholic hepatitis: establishing a new frontier by ignoring the rule?. Annals of Translational Medicine, 2018, 6, 411-411.	0.7	0
105	Trimming the fat in non-alcoholic fatty liver disease management. Canadian Liver Journal, 2019, 2, 49-50.	0.3	0
106	Seroprevalence of hepatitis B in previously undiagnosed patients: A community screening study. Canadian Liver Journal, 0, , .	0.3	0
107	Title is missing!. , 2020, 15, e0229070.		0
108	Title is missing!. , 2020, 15, e0229070.		0

## ERIC M YOSHIDA

#	Article	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0229070.		0
110	Title is missing!. , 2020, 15, e0229070.		0
111	Clinical characterization of patients with primary biliary cholangitis: A report from multiple Canadian centres. Canadian Liver Journal, 0, , .	0.3	0
112	Real-world treatment patterns, clinical outcomes, and health care resource utilization in advanced unresectable hepatocellular carcinoma. Canadian Liver Journal, 0, , .	0.3	0
113	COVID-19 infection in liver transplant recipients: Clinical features and outcomes from a Canadian multicentre cohort. Canadian Liver Journal, 0, , .	0.3	O